LUNGevity Foundation shared a post on X:
“Great talk by Dr. Shilpa Singh looking at Cyclin A/B RxL Macrocyclic Inhibitors in SCLC with high E2F activity.
Beautiful example of bridging lab to clinical research. Phase 1 trial is recruiting.”
More posts featuring LUNGevity Foundation.
